Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Canada Postdoctoral Research Award (CPRA) program

Direct Payment

$140,000.00

Intersection of hypertension and tau pathology in cognitive decline

EF 2025-26

Résumé
Hypertension (HTN), particularly in mid-life, is a well-known risk factor in Alzheimer's disease and related dementias (AD/ADRD), but the underlying mechanisms are unclear. AD is characterized, in part, by the accumulation of toxic proteins in the brain. Autopsy and biomarker studies have found that one such protein, known as pathological tau (p-tau), is higher in patients with HTN, suggesting that HTN elevates AD risk by increasing the amount of p-tau in the brain. However, since mixed dementia, which combines both vascular and AD pathology, is the most common cause of cognitive decline, it is unclear whether the relationship between HTN and tau pathology is causative or incidental. Under normal conditions, solutes, including tau, are cleared from the brain through waste removal pathways, but in HTN, factors which influence the efficiency of these pathways are disrupted, raising the possibility that HTN increases p-tau burden in the brain by disrupting its removal. Based on these premises, we hypothesize that HTN promotes p-tau consequent to impaired clearance, which ultimately leads to cognitive impairment. These hypotheses will be tested in a highly translational mouse model of salt-sensitive HTN, which in humans is common and difficult to control. In aim 1, we will first determine the time points at which vascular dysfunction, tau pathology, and cognitive impairment develop in HTN, then study the contributions of p-tau to the cognitive impairment by using anti-tau antibodies to prevent its formation. In aim 2, we will use cutting edge imaging techniques to investigate how HTN affects the clearance of tau from the brain. In aim 3, we will determine if rescue of neurovascular functions, which regulate cerebral blood flow and are disrupted in HTN, can restore tau clearance to normal levels. These studies, collectively, will provide new insight into the role of HTN in AD/ADRD as well as identify new strategies to preserve cognitive health in patients with HTN.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
537877
Name
Pacholko Anthony G
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Intersection of hypertension and tau pathology in cognitive decline
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Alzheimer'S Disease And Related Dementias; Cerebral Blood Flow; Cognitive Decline; Cognitive Testing; Hypertension; Idisco Imaging; In Vivo Imaging; Tau Pathology
Abstract
Hypertension (HTN), particularly in mid-life, is a well-known risk factor in Alzheimer's disease and related dementias (AD/ADRD), but the underlying mechanisms are unclear. AD is characterized, in part, by the accumulation of toxic proteins in the brain. Autopsy and biomarker studies have found that one such protein, known as pathological tau (p-tau), is higher in patients with HTN, suggesting that HTN elevates AD risk by increasing the amount of p-tau in the brain. However, since mixed dementia, which combines both vascular and AD pathology, is the most common cause of cognitive decline, it is unclear whether the relationship between HTN and tau pathology is causative or incidental. Under normal conditions, solutes, including tau, are cleared from the brain through waste removal pathways, but in HTN, factors which influence the efficiency of these pathways are disrupted, raising the possibility that HTN increases p-tau burden in the brain by disrupting its removal. Based on these premises, we hypothesize that HTN promotes p-tau consequent to impaired clearance, which ultimately leads to cognitive impairment. These hypotheses will be tested in a highly translational mouse model of salt-sensitive HTN, which in humans is common and difficult to control. In aim 1, we will first determine the time points at which vascular dysfunction, tau pathology, and cognitive impairment develop in HTN, then study the contributions of p-tau to the cognitive impairment by using anti-tau antibodies to prevent its formation. In aim 2, we will use cutting edge imaging techniques to investigate how HTN affects the clearance of tau from the brain. In aim 3, we will determine if rescue of neurovascular functions, which regulate cerebral blood flow and are disrupted in HTN, can restore tau clearance to normal levels. These studies, collectively, will provide new insight into the role of HTN in AD/ADRD as well as identify new strategies to preserve cognitive health in patients with HTN.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Pacholko, Anthony G
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~